Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer

Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:

”ANTHER Trial Results: Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer. At a 10.3-year follow-up, dose-dense treatment showed:

• Better recurrence-free survival (HR 0.80; P = 0.030). 
• Better event-free survival (HR 0.78; P = 0.009). 
• Improved distant disease-free survival (HR 0.79; P = 0.030).
• There was no significant difference in overall survival (HR 0.82; P = 0.109).

Dose-dense regimens significantly improve breast cancer-free survival and disease-free survival compared to standard chemotherapy.”

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, Jonas Bergh.

Source: Ivan R. Gonzalez/X